Israel-based developer of protein-free alga-mimetic tissue adhesives, Sealantis, has reported positive results from its first prospective, single-arm, non-randomised clinical study that tested the safety and performance of its protein-free bioresorbable sealant Seal-V.

The latest trial involved 23 patients and 38 vascular reconstruction sites using various types of graft materials and met all primary and secondary endpoints. The study was conducted in three medical centres in Israel.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Following these fruitful results, the company plans to launch the product in European markets later in 2014.

According to the company, Seal-V is a bioresorbable sealant designed to produce haemostasis by mechanically sealing areas of leakage risk for surgical reconstruction of large blood vessels, including bypass procedures and arterio-venous access for haemodialysis.

"Our intention is to make Seal-V available to vascular surgeons in Europe later this year."

The study results revealed that the average time to haemostasis (bleeding cessation) using Seal-V was approximately 36 seconds. This demonstrated the benefits in using Seal-V to save blood and time in the operating room.

In addition, no device-related complications or adverse events were reported during the three-month follow-up period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In August 2013, the company obtained CE Mark approval for its Seal-V and is currently being used in several clinical centres in Germany, towards the coming product launch.

Sealantis CEO Tomer Fuchs said Seal-V performed well in the clinical study.

"We have received positive feedback and increasing interest from surgeons and from the market," Fuchs said. "Our intention is to make Seal-V available to vascular surgeons in Europe later this year."

The sealants are developed based on an alga-mimetic formulation to bind strongly to both native blood vessels and synthetic grafts, even in wet and moist conditions.

In addition, the protein-free composition relieves Seal-V from risks associated with the use of protein-based products.

Currently, the company also has other products in the pipeline including gastro-intestinal sealant for preventing leakage of bowel content after surgery, an adhesive for plastic and esthetic surgeries, and innovative adhesive-drug formulations for site-specific drug delivery.

According to GlobalData estimates, the tissue sealants market in Europe valued at $298.7m in 2012 and is expected to grow at a CAGR of 6.7% to reach $470.4m by 2019.